This website is a global information resource. It is intended for healthcare professionals outside of the United States of America (US) who are interested in information on TECENTRIQ®. If you are a US healthcare professional click hereopens in a new tab
The product has received EMA approval. The registration status and approved product labels of TECENTRIQ® may not be the same in different countries. This website is not country-specific and therefore may contain information which is not applicable to your country. Please refer to your local Prescribing Information for full details.
This website has been updated according to the latest EMA approval in February 2021.
NSCLC represents approximately 85% of all new lung cancer diagnoses. In metastatic NSCLC, TECENTRIQ—alone or in combination with cytotoxic therapy—has helped improve OS and has extended survival without progression in a broad patient population.1-5
Now, with adjuvant TECENTRIQ, you give people with PD-L1-high (≥50%) resected stage II-III* NSCLC, excluding EGFR/ALK+ disease the possibility of living longer free of their disease. 6,7,11
Patients with resected NSCLC remain at high risk of cancer recurrence despite adjuvant chemotherapy. For up to ~75% of patients with resected NSCLC, cancer returns within 5 years.8
ALK, anaplastic large-cell lymphoma kinase; EGFR, epidermal growth factor receptor; NSCLC, non-small-cell lung cancer; OS, overall survival; PD-L1, programmed death-ligand 1; TNM, The Tumour/Nodal Involvement/Metastatic Spread Classification of Malignant Tumours.
*Stage II-IIIA (TNM 7th edition)/select stage II-IIIB (TNM 8th edition).7,9
†These Phase 3 studies are not representative of all Phase 3 TECENTRIQ studies.
IMpower010 was a Phase 3 study (n=1280) evaluating adjuvant TECENTRIQ in patients with completely resected stage IB-IIIA NSCLC according to TNM 7th edition staging. Patients were treated with up to 4 cycles of cisplatin-based chemotherapy before randomisation (n=1005) to treatment with TECENTRIQ for 16 cycles or best supportive care (BSC).6,7
The primary endpoint was investigator-assessed DFS. Key secondary endpoints included OS in the ITT population and DFS in the PD-L1-high stage II-IIIA population.7
*Stage II-IIIA (TNM 7th edition)/select stage II-IIIB (TNM 8th edition).7,9
A global 3-arm study in patients (n=1202) with chemotherapy-naïve non squamous metastatic NSCLC. Patients were randomised to receive TECENTRIQ + carboplatin/paclitaxel, TECENTRIQ + Avastin + carboplatin/paclitaxel, or Avastin + carboplatin/paclitaxel, respectively, until disease progression or unacceptable toxicity. Primary endpoints included OS and PFS in the intention-to-treat wild-type (ITT-WT) population (ie. EGFRwt and ALKwt).8
This video has been produced and funded by VJ Oncology. F. Hoffmann-La Roche Ltd did not participate in the filming or editing of this video. The video reflects independent opinions of the speaker. F. Hoffmann-La Roche Ltd has been given permission to publish this video here. Prof. Martin Reck has also provided explicit permission for this video to be presented here.
A Phase 3 study in patients (n=723) with chemotherapy-naïve unresectable stage IV NSCLC randomised to receive induction therapy with TECENTRIQ + carboplatin/nab-paclitaxel or carboplatin/nab-paclitaxel followed by TECENTRIQ or best supportive care/pemetrexed, respectively, until disease progression or unacceptable toxicity. Primary endpoints were PFS and OS in the intention-to-treat wild-type (ITT-WT) population (ie. EGFRwt and ALKwt).13
A Phase 3 study in patients (n=572) with chemotherapy-naïve stage IV NSCLC randomised to receive induction therapy with TECENTRIQ or carboplatin (or cisplatin + pemetrexed [non-
squamous] or cisplatin + gemcitabine [squamous]) followed by TECENTRIQ or best supportive care (non-squamous) or pemetrexed (squamous), respectively, until disease progression or loss of clinical benefit. Primary endpoints included OS.12
A Phase 3 study in patients (n=1225) with locally advanced or metastatic NSCLC who progressed during or following a platinum-based regimen. Patients were randomised to receive TECENTRIQ or docetaxel until disease progression or unacceptable toxicity. The primary endpoint was OS.4,13
Patients with Stage lllb/IV NSCLC who experience disease progression after 1–2 lines of standard chemotherapy received TECENTRIQ 1200 mg IV q3w until disease progression or unacceptable toxicity. The primary endpoint was treatment-related safety. 15
Explore more
Curious to see more resources and download material?
At Roche, we believe in a shared purpose in improving the care and treatment of patients living with difficult to treat cancers. We understand and empathise with the demands you face managing the needs of these patients.
Roche is committed to exploring new treatment options to individualise treatment and meet patients’ needs. TECENTRIQ has proven efficacy as monotherapy as well as in combination with other medicines and we are committed to exploring new combinations to improve patient outcomes (ref. SmPC).
TECENTRIQ is an anti PD-L1 cancer immunotherapy that specifically targets PD-L1 on tumour and tumour-infiltrating immune cells across a broad range of solid tumours. TECENTRIQ offers a pioneering, targeted treatment with proven efficacy and an acceptable tolerability profile (ref. SmPC). Please see the specific indications for more information.